GTx, Ipsen deal

GTx and Ipsen terminated a 2006 deal to develop and commercialize GTx's toremifene 80 mg to reduce the risk of fractures in men with prostate cancer receiving androgen deprivation

Read the full 298 word article

How to gain access

Continue reading with a
two-week free trial.